Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions

ICI, immune checkpoint inhibitor. Credit: Jian-Hong Zhong, Liang Ma, Le Li, Zhen-Zhen Li Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of cancer-related deaths. The primary curative treatments for HCC are liver transplantation, hepatectomy, and local ablation. However, the recurrence rate of HCC following hepatectomy or ablation remains alarmingly high, up to 70%, severely impacting patient prognosis and overall survival (OS). To mitigate postoperative recurrence and improve patient outcomes, various adjuvant therapies have been explored. Despite the efficacy of several adjuvant treatments in reducing recurrence rates and enhancing survival, there is Read More